

1 **The post-COVID-19 population has a high prevalence of crossreactive antibodies to spikes**
2 **from all *Orthocoronavirinae* genera**

3
4 Gagandeep Singh^{1,2}, Anass Abbad^{1,2}, Giulio Kleiner^{1,2}, Komal Srivastava^{1,2}, Charles Gleason^{1,2}, PARIS Study
5 Group^{1,2}, Juan Manuel Carreño^{1,2}, Viviana Simon^{1,2,3,4,5} and Florian Krammer^{1,2,3*}

6
7 ¹*Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA*

8 ²*Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount*
9 *Sinai, New York, NY, USA*

10 ³*Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai,*
11 *New York, NY, USA*

12 ⁴*Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New*
13 *York, NY, USA*

14 ⁵*The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York,*
15 *NY, USA*

16 *To whom correspondence should be addressed: florian.krammer@mssm.edu

17
18 #PARIS Study Group (alphabetical order): Dalles Andre, Maria C Bermúdez-González, Dominika
19 Bielak, Gianna Cai, Christian Cognigni, Yuexing Chen, Miriam Fried, Hyun Min Kang, Neko Lyttle, Jacob
20 Mauldin, Brian Monahan, Sara Morris, Jessica Nardulli, Annika Oostenink, Ashley-Beathrese Salimbangon,
21 Leeba Sullivan, Morgan Van Kesteren, Temima Yellin

22

23 **Keywords:** SARS-CoV-2 immunity, antibodies, cross-reactivity, Orthocoronaviridae

24 **Abstract**

25 The Orthocoronaviridae subfamily is large comprising four highly divergent genera. Four seasonal
26 coronaviruses were circulating in humans prior to the coronavirus disease 2019 (COVID-19) pandemic.
27 Infection with these viruses induced antibody responses that are relatively narrow with little cross-
28 reactivity to spike proteins of other coronaviruses. Here, we report that infection with and vaccination
29 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces broadly crossreactive
30 binding antibodies to spikes from a wide range of coronaviruses including members of the sarbecovirus
31 subgenus, betacoronaviruses including Middle Eastern respiratory syndrome coronavirus (MERS CoV),
32 and extending to alpha-, gamma- and delta-coronavirus spikes. These data show that the coronavirus
33 spike antibody landscape in humans has profoundly been changed and broadened as a result of the SARS-
34 CoV-2 pandemic. While we do not understand the functionality of these crossreactive antibodies, they
35 may lead to enhanced resistance of the population to infection with newly emerging coronaviruses with
36 pandemic potential.

37

38 Main text

39 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and vaccinations induce binding
40 and neutralizing antibodies to the spike protein of this new virus in humans [1, 2]. Initially, these responses
41 led to protection from symptomatic disease as shown in a number of clinical trials. However, with the
42 emergence of variants of concern, especially Omicron and its sub-variants, protection against
43 symptomatic disease decreased since these new variants escaped the neutralizing antibody response
44 induced by spike proteins from the ancestral SARS-CoV-2. However, it has been reported that binding
45 antibody to spike protein are much better maintained against the variants as compared to neutralizing
46 activity [3]. These binding antibodies may – in addition to T-cell immunity – contribute to the mostly
47 maintained protection from severe disease [4].

48 Here, we wanted to explore how cross-reactive antibodies induced by SARS-CoV-2 infection or vaccination
49 bind beyond the spike protein of SARS-CoV-2 and its variants. We expressed a panel of coronavirus spikes
50 representative of all *Orthocoronavirinae* genera. We generated 21 recombinant spikes representing the
51 five betacoronavirus (β -CoV) subgenera (sarbecoviruses, hibecoviruses, merbecoviruses, nobecoviruses
52 and embecoviruses) as well the alphacoronavirus (α -CoV), gammacoronavirus (γ -CoV) and
53 deltacoronavirus (δ -CoV) genera (**Figure 1A** and **Supplementary Table 1**). Using an established enzyme-
54 linked immunosorbent assay (ELISA) [5], we tested longitudinal sera from 10 individuals who received the
55 mRNA coronavirus disease 2019 (COVID-19) vaccine and from 10 individuals who received the vaccine
56 after an initial SARS-CoV-2 infection (**Supplementary Table 2**). Sera were taken before vaccination, post-
57 1st dose (range 16-25 days for the vaccine-only group and 15-23 days for the infection-vaccination group)
58 and post-2nd dose (range 14-28 days for the vaccine-only group and 16-29 days for the infection-
59 vaccination group). Binding to SARS-CoV-2 ancestral and variant spikes was induced by vaccination as
60 expected and was detectable before vaccination in people with pre-existing immunity (**Figure 1B-D**).
61 Comparable binding was found for the SARS-CoV-1 spike and titers were also high against three other
62 non-SARS-CoV-2 sarbecovirus spikes tested (**Figure 1E-H**). In addition, an increase in binding was detected
63 to a hibecovirus spike and merbecovirus spikes although at a lower level (**Figure 1I** and **L-O**). COVID-19
64 vaccine-associated increases were only detected for one of the two nobecovirus spikes tested (**Figure 1J**
65 and **K**) but reactivity to embecoviruses was induced to some degree (**Figure 1P-R**) and – as expected –
66 higher at pre-vaccination baseline since two of the spikes tested are from embecoviruses circulating in
67 humans (OC43 and HKU1). No increase in reactivity was detected against the seasonal α -CoV spikes but
68 pre-vaccination baseline titers to 229E spike were detectable while reactivity to NL63 spike was much
69 lower (**Figure 1S** and **T**). Interestingly, there was also an induction of antibodies to the γ -CoV spike of
70 HKU15 but not to the δ -CoV of HKU22 (**Figure 1U** and **V**). In general, most SARS-CoV-2 infected individuals
71 already had titers to these spikes even before they got vaccinated. These data suggested that SARS-CoV-
72 2 infection and vaccination can induce cross-reactive anti-spike antibodies.

73 We next investigated how different immune histories influence pan-coronavirus seroreactivity. We tested
74 sera from different exposure groups including pre-pandemic samples (n=15, collected between 2018-
75 2019), samples from convalescent individuals (n=16, collected at 23-87 days post infection), individuals
76 who got two doses of COVID-19 mRNA vaccines (n=20, range of 14-36 days post-2nd dose), individuals who
77 got three doses of COVID-19 mRNA vaccines (n=20, range of 14-33 days post-3rd dose), individuals who
78 were infected and then got two doses of COVID-19 mRNA vaccines (n=20, range of 15-39 days post-2nd
79 dose) and individuals who got infected and three doses of COVID-19 mRNA vaccines (n=9, range of 14-30
80 days post-3rd dose). More information regarding the specific samples can be found in **Supplementary**
81 **Table 3**. Analysis of pre-pandemic sera showed reactivity to the β -CoV spikes from two human seasonal
82 coronaviruses, OC43 and HKU1. Interestingly, there was also strong reactivity, comparable to OC43, to
83 the spike of the bovine coronavirus (BCoV) with sera from all study participants having reactivity above

84 the limit of detection (LoD) (**Figure 2A, Extended Figure 1A**). Reactivity against spikes from seasonal α -
85 CoVs, NL63 and 229E was also found. Similar to data shown in **Figure 1S and T**, reactivity to NL63 was
86 much lower than for 229E. For sera from SARS-CoV-2 convalescent individuals, we observed strong
87 reactivity to SARS-CoV-2 spikes with elevated reactivity to spikes of many β -CoV with the exception of the
88 nobecovirus spikes from GCCDC1 and HKU9 (**Figure 2B**). Sera from several study participants (44% and
89 56% respectively) even had detectible reactivity to the γ -CoV spike of HKU15 and δ -CoV spike of HKU22
90 (**Extended Figure 1B**). By receiving two or three doses of COVID-19 mRNA vaccines the reactivity pattern
91 changed slightly. With two doses of the vaccine, higher reactivity to β -CoV spikes could be observed
92 (**Figure 2C**). With three doses of the mRNA vaccine, high and relatively uniform reactivity to sarbecoviruses
93 can be measured (**Figure 2D**). In addition, the percentage of individuals who had detectible reactivity in
94 the 2x and 3x mRNA vaccinated groups was high across all tested spikes (**Extended Figure 1C and D**). Sera
95 from people who had received three vaccine doses cross-reacted with all spikes except the spikes of the
96 the nobecoviruses GCCDC1 and HKU9 and the γ -CoV spike of HKU15 and to the δ -CoV of HKU22 where
97 about approximately 20-55% of individuals had reactivity (**Extended Figure 1D**). Similarly strong reactivity
98 across the board was also detected in individuals who had been infected and then vaccinated 2x or 3x
99 with COVID-19 mRNA vaccines (**Figures 2E and F, Extended Figure 1E and F**).

100 Several of our observations from these experiments are interesting. Even in pre-COVID-19 sera, the
101 prevalence and titers against the spike of β -CoV BCoV are almost as high as against the spike of seasonal
102 β -CoV OC43. This indicates an antigenic relatedness of the BCoV and OC43 spikes. It has been
103 hypothesized that OC43 shares a common ancestor with BCoV and may have split off around 1890 [6].
104 This split would coincide with the 'Russian flu' pandemic of 1889/1890 and it has been hypothesized that
105 this pandemic was, indeed, caused by an OC43 ancestor which jumped from cattle into humans [7]. The
106 crossreactivity found may perhaps further support this hypothesis and also explain why zoonotic
107 infections in humans with BCoV are rare even though the virus can infect children [8]. In addition, the
108 titers as well as the percentage of positive individuals for the seasonal α -CoV 229E are much higher than
109 for the seasonal α -CoV NL63. These differences may point perhaps to an inherent difference in
110 immunogenicity, antibody durability or represent an artifact of the protein used in the ELISA.
111 Furthermore, from our longitudinal sample set, we noted that COVID-19 mRNA vaccination induces
112 antibodies to diverse spike proteins including many β -CoVs spikes as well as δ -CoV spikes. As previously
113 reported, backboosting to OC43 and HKU (and BCoV) was also observed [9, 10], but little to no induction
114 of antibodies was seen against α -CoV spikes, the tested γ -CoV spike or the spikes from the nobecoviruses
115 subgenus of the β -CoV. At a cross-sectional level we observed that sera from individuals infected with
116 SARS-CoV-2 already show relatively broad reactivity across β -CoVs spikes with about half of the individuals
117 having also some reactivity to δ -CoV and γ -CoV spikes. COVID-19 mRNA vaccination induced similar
118 crossreactivity. However, especially after three vaccine doses, there seems to be a bias towards
119 sarbecoviruses with a clear drop towards other non-seasonal β -CoV spikes. It is important to note that
120 after mRNA vaccination with the original vaccine containing the ancestral SARS-CoV-2 spike, titers against
121 diverse sarbecovirus spikes are as high as against the Omicron spike. This may suggest, that the protection
122 from severe disease that we observe against Omicron sublineages perhaps also applies to other, diverse
123 sabecoviruses (e.g., SARS-CoV-1, HKU3-8, SX2013, BM48-31) which may (re)-emerge in the future as
124 human pathogens. While these cross-reactive antibodies may not neutralize more distantly related
125 viruses, they may still afford protection via Fc-mediated effector functions.

126 Another interesting aspect is the question of which epitopes these crossreactive antibodies target.
127 Crossreactivity within the sarbecoviruses likely targets the receptor binding domain RBD but also different
128 epitopes on the S2 subunit. Cross-reactivity to other β -CoV spikes is likely mediated mostly by S2 targeting
129 antibodies since the receptor binding domain (RBD) is probably too divergent. Such antibodies have been
130 isolated with some of them having neutralizing activity although at low potency [9, 11-13]. Finally,

131 crossreactivity to α -CoV, δ -CoVs and γ -CoVs is likely due to more rare antibodies that target the fusion
132 peptide in the S2 domain. These antibodies have also been isolated and they exert neutralizing activity to
133 some extent [14, 15]. However, it would be helpful to isolate more mAbs with different reactivity profiles
134 to understand their characteristics better and determine if they indeed can contribute to protection *in*
135 *vivo*. Of note, monoclonal antibody therapeutics and prophylactics have been very efficient treatment
136 options for COVID-19, but antigenic changes of SARS-CoV-2 have rendered them irrelevant. Perhaps
137 antibodies that target more conserved epitopes, even if they have lower neutralizing potency, could be a
138 more sustainable solution.

139 In summary, we found a high prevalence of antibodies that crossreact to spike proteins from all four
140 *Orthocoronavirinae* genera. It is entirely possible that the global population, which is hyperimmunized to
141 SARS-CoV-2 through infection and vaccination, has now build more resistance to the many members
142 coronavirus family in general.

143

144

145 **Acknowledgements**

146 We thank all the participants of our longitudinal PARIS study for their generous and continued support of
147 research. We would like to thank Dr. D. Noah Sather from the University of Washington for providing the
148 Beta and BA.1 spike protein used in this study and Drs. Kizzmekia Corbett and Barney Graham for providing
149 229E, NL63, HKU1 and OC43 constructs. This effort was supported by the Serological Sciences Network
150 (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health,
151 under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication
152 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor
153 does mention of trade names, commercial products or organizations imply endorsement by the U.S.
154 Government. This work was also partially funded by the Centers of Excellence for Influenza Research and
155 Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for Influenza Research
156 and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza Vaccine Innovation
157 Centers (CIVICs contract # 75N93019C00051) and by institutional funds.

158 **Conflict of interest statement**

159 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
160 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr.
161 Simon is also listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company,
162 Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer
163 (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a
164 co-founder and scientific advisory board member of CastleVax. The Krammer laboratory is also
165 collaborating with Pfizer on animal models of SARS-CoV-2.

166

167 **References**

- 168 [1] Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody
169 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med*. 2021.
170 [2] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing
171 antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020;370:1227-30.
172 [3] Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H, et al. Activity of convalescent
173 and vaccine serum against SARS-CoV-2 Omicron. *Nature*. 2021.
174 [4] Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, et al. Assessing
175 vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a
176 meeting of the World Health Organization. *Vaccine*. 2022;40:3516-27.
177 [5] Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological
178 assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020.
179 [6] Vijgen L, Keyaerts E, Moës E, Thoelen I, Wollants E, Lemey P, et al. Complete genomic sequence of
180 human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus
181 transmission event. *J Virol*. 2005;79:1595-604.
182 [7] Brüssow H, Brüssow L. Clinical evidence that the pandemic from 1889 to 1891 commonly called the
183 Russian flu might have been an earlier coronavirus pandemic. *Microb Biotechnol*. 2021;14:1860-70.
184 [8] Zhang XM, Herbst W, Kousoulas KG, Storz J. Biological and genetic characterization of a
185 hemagglutinating coronavirus isolated from a diarrhoeic child. *J Med Virol*. 1994;44:152-61.
186 [9] Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, et al. SARS-CoV-2 mRNA
187 vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell*. 2021;184:3936-48.e10.
188 [10] Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, et al. Immunological
189 imprinting of the antibody response in COVID-19 patients. *Nat Commun*. 2021;12:3781.
190 [11] Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, et al. Broadly neutralizing anti-S2 antibodies
191 protect against all three human betacoronaviruses that cause deadly disease. *Immunity*. 2023;56:669-
192 86.e7.
193 [12] Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, et al. Broad
194 betacoronavirus neutralization by a stem helix-specific human antibody. *Science*. 2021;373:1109-16.
195 [13] Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. Cross-reactive serum and
196 memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nat*
197 *Commun*. 2021;12:2938.
198 [14] Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, et al. Broadly neutralizing antibodies target the
199 coronavirus fusion peptide. *Science*. 2022;377:728-35.
200 [15] Low JS, Jerak J, Tortorici MA, McCallum M, Pinto D, Cassotta A, et al. ACE2-binding exposes the
201 SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. *Science*. 2022;377:735-42.
202 [16] Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2
203 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test
204 Setup. *Curr Protoc Microbiol*. 2020;57:e100.
205 [17] Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and
206 structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A*.
207 2017;114:E7348-E57.
208 [18] Simon V, Kota V, Bloomquist RF, Hanley HB, Forgacs D, Pahwa S, et al. PARIS and SPARTA: Finding
209 the Achilles' Heel of SARS-CoV-2. *mSphere*. 2022;7:e0017922.
210 [19] Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human
211 aminopeptidase N is a receptor for human coronavirus 229E. *Nature*. 1992;357:420-2.

- 212 [20] Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63
213 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. *Proc Natl Acad*
214 *Sci U S A*. 2005;102:7988-93.
- 215 [21] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-
216 2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020;5:562-9.
- 217 [22] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a
218 functional receptor for the SARS coronavirus. *Nature*. 2003;426:450-4.
- 219 [23] Wells HL, Letko M, Lasso G, Ssebide B, Nziza J, Byarugaba DK, et al. The evolutionary history of ACE2
220 usage within the coronavirus subgenus. *Virus Evol*. 2021;7:veab007.
- 221 [24] Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, et al. Adenosine
222 deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East
223 respiratory syndrome coronavirus. *J Virol*. 2014;88:1834-8.
- 224 [25] Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C
225 betacoronavirus to *Tylonycteris* bat coronavirus HKU4 and *Pipistrellus* bat coronavirus HKU5. *Emerg*
226 *Microbes Infect*. 2012;1:e35.
- 227 [26] Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, et al. Receptor usage and cell entry of bat coronavirus
228 HKU4 provide insight into bat-to-human transmission of MERS coronavirus. *Proc Natl Acad Sci U S A*.
229 2014;111:12516-21.
- 230 [27] Woo PC, Wang M, Lau SK, Xu H, Poon RW, Guo R, et al. Comparative analysis of twelve genomes of
231 three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. *J Virol*.
232 2007;81:1574-85.
- 233 [28] Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the
234 phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific
235 virus from an African bat. *J Virol*. 2014;88:11297-303.
- 236 [29] Xiong Q, Cao L, Ma C, Tortorici MA, Liu C, Si J, et al. Close relatives of MERS-CoV in bats use ACE2 as
237 their functional receptors. *Nature*. 2022;612:748-57.
- 238 [30] Huang C, Liu WJ, Xu W, Jin T, Zhao Y, Song J, et al. A Bat-Derived Putative Cross-Family Recombinant
239 Coronavirus with a Reovirus Gene. *PLoS Pathog*. 2016;12:e1005883.
- 240 [31] Wu Z, Yang L, Ren X, Zhang J, Yang F, Zhang S, et al. ORF8-Related Genetic Evidence for Chinese
241 Horseshoe Bats as the Source of Human Severe Acute Respiratory Syndrome Coronavirus. *J Infect Dis*.
242 2016;213:579-83.
- 243 [32] Schultze B, Herrler G. Recognition of cellular receptors by bovine coronavirus. *Arch Virol Suppl*.
244 1994;9:451-9.
- 245 [33] Hulswit RJG, Lang Y, Bakkers MJG, Li W, Li Z, Schouten A, et al. Human coronaviruses OC43 and
246 HKU1 bind to 9-. *Proc Natl Acad Sci U S A*. 2019;116:2681-90.
- 247 [34] Yuan Y, Zu S, Zhang Y, Zhao F, Jin X, Hu H. Porcine Deltacoronavirus Utilizes Sialic Acid as an
248 Attachment Receptor and Trypsin Can Influence the Binding Activity. *Viruses*. 2021;13.
- 249 [35] Wang L, Maddox C, Terio K, Lanka S, Fredrickson R, Novick B, et al. Detection and Characterization
250 of New Coronavirus in Bottlenose Dolphin, United States, 2019. *Emerg Infect Dis*. 2020;26:1610-2.

251

252

253 **Online Methods**

254 **Recombinant proteins expression**

255 Mammalian expression vectors encoding the ectodomain of spike proteins from SARS-CoV-1 (GenBank:
256 875 AAP13441.1), SARS-CoV-2 (GenBank: MN908947.3), HKU3-8 (GenBank: ADE34766.1), SX2013
257 (GenBank: AIA62300.1), BM48-31(GenBank: YP_003858584.1), SARS-CoV-2 Omicron (GenBank:
258 UFT26501.1), MERS-CoV (GenBank: AXP07355.1), HKU4 (GenBank: YP_001039953.1), HKU5 (GenBank:
259 YP_001039962.1), HKU9 (YP_001039971.1), GCCDC1 (GenBank: QKF94914.1), Zhejiang2013, bat Hp
260 (GenBank: YP_009072440.1) HKU15 (GenBank: YP_009513021.1), HKU22 (GenBank: AHB63508.1), BCoV,
261 bovine coronavirus (GenBank: AAA66399.1), Neo CoV, Coronavirus Neoromicia (Genbank: AGY29650.2),
262 229E (Genbank: NP_073551.1), NL63 (GenBank AFV53148.1), OC43 (Genbank: KF963240.1) and HKU1
263 (Genbank: AGW27881.1) (see **Supplementary Table 1** for more information on virus isolates, host and
264 receptor) with a C-terminal thrombin cleavage site, T4 foldon trimerization domain and hexahistidine tag
265 were constructed as described earlier [5, 16]. The constructs also contain the “2P” stabilizing mutations
266 [17] and known or putative S1-S2 cleavage sites were removed. Proteins were purified from transiently-
267 transfected Expi293F cells with each respective plasmid. Cell-free supernatant was harvested after 3 days
268 post transfection and his-tagged proteins were purified by gravity chromatography using Ni²⁺-nitriloacetic
269 acid (NTA) agarose (Qiagen). Proteins were eluted and buffer was exchanged using Amicon centrifugal
270 units (EMD Millipore) and all recombinant proteins were finally re-suspended in phosphate buffered saline
271 (PBS) as described [16]. Proteins were run on sodium dodecyl sulfate polyacrylamide gel electrophoresis
272 (SDS-PAGE) gels under reducing conditions for quality control and stored at -80°C until use.

273 **ELISA**

274 Antibody titers in in serum samples were assessed using a research grade ELISA [5, 16] using recombinant
275 versions of full-length spike (S) proteins of different coronaviruses. Briefly, Immulon 4 HBX 96-well
276 microtiter plates (Thermo Fisher Scientific) were coated overnight at 4 °C with 50 µl per well of a 2 µg/ml
277 solution of each respective recombinant protein resuspended in PBS (Gibco; cat. no. 10010-031). The
278 next morning, plates were washed 3 times with PBS supplemented with 0.1% Tween-20 using an
279 automatic plate washer (BioTek 405TS microplate washer) and blocked with 200 µl per well of PBST
280 containing 3% milk powder (AmericanBio) for 1 h at room temperature (RT). Blocking solution was
281 removed, and initial dilutions (1:100) of heat-inactivated serum (in PBS-T 1% milk powder) were added to
282 the plates, followed by 2-fold serial dilutions and 2h incubation at RT. Next, plates were washed three
283 times with PBS-T and 50 µl per well of the pre-diluted secondary anti-human IgG (Fab-specific) horseradish
284 peroxidase (HRP) antibody (produced in goat; Sigma-Aldrich, cat. no. A0293, RRID: AB_257875) diluted
285 1:9,000 in PBS-T containing 1% milk powder were added for 1 h. Plates were again washed three times
286 with 0.1% PBST, the substrate o-phenylenediamine dihydrochloride (OPD) (SIGMAFAST) was added (100
287 µl per well) for 10 min, followed by an addition of 3M hydrochloric acid (50 µl per well; Thermo Fisher
288 Scientific) to stop the reaction. Optical density (OD) was measured at a wavelength of 490 nm using a
289 plate reader (BioTek, Synergy H1 microplate reader). The area under the curve (AUC) values were
290 calculated and plotted using Prism 9 software (GraphPad).

291 **Human serum samples**

292 Human serum samples were obtained from study participants in the longitudinal observational Protection
293 Associated with Rapid Immunity to SARS-CoV-2 (PARIS) study [18]. This cohort follows health care workers
294 longitudinally since April 2020. The study was reviewed and approved by the Icahn school of Medicine at
295 Mount Sinai Institutional Review Board (IRB-20-03374). All participants provided informed consent and
296 HIPAA Authorization prior to sample and data collection. All participants provided permission for sample

297 banking and sharing. The participants did not receive compensation. All biospecimen were coded and
298 stored at -80°C .

299 We used longitudinal serum samples collected from 20 adult study participants. 10/20 of the study
300 participants (50%) were infected with SARS-CoV-2 prior to the first vaccine dose and were seropositive
301 prior to vaccination (pre-infected group). 10/20 study participants (50%) had no previous SARS-CoV-2
302 infection history and were seronegative for SARS-CoV-2 antibodies prior to vaccination (naive group).
303 Participants received two doses of either the Moderna mRNA-1273 vaccine or the Pfizer-BioNTech
304 BNT162b2 vaccine. Demographics of seropositive and seronegative study participants and sample
305 collection time points from each individual are summarized in **Supplementary Table 2**.

306 For the antigenic landscape characterization against various coronaviruses, we selected 85 serum samples
307 from 54 participants. 20 out of 54 participants were seronegative prior to vaccination while 34/54 had
308 COVID-19 prior to vaccination. All participants with pre-vaccination immunity were infected in 2020 when
309 only ancestral SARS-CoV-2 strains circulated in the New York metropolitan area. Convalescent samples
310 ($n = 15$) were obtained within three months of SARS-CoV-2 infection (average: 58 days, range: 23–87 days)
311 whereas the post-vaccination samples were collected on average 23 days (range: 14–39 days) after the
312 second dose [$n = 40$; where $n = 20$ Pfizer $2\times$ (10 individuals with prior infection and 10 individuals with no
313 infection) and $n = 20$ Moderna $2\times$ (10 individuals with prior infection and 10 individuals with no infection)]
314 or 19 days (range: 14–33 days) after the third booster [$n = 30$; 20 Pfizer $3\times$ (10 individuals with prior
315 infection and 10 individuals with no infection) and 10 Moderna $3\times$) vaccine dose. Pre-pandemic human
316 serum samples were collected before the COVID-19 pandemic. Demographics of participants and sample
317 collection time points from each individual are summarized in **Supplementary Table 3**.

318

319 **Supplementary Tables**

320 **Supplementary Table 1. Information on the viral isolates used for recombinant spike protein** 321 **generation.**

Virus	Genus (subgenus)	Accession #	Host Species	Receptor	Reference
229E	α -CoV	NP_073551.1	<i>Homo sapiens</i>	Human aminopeptidase N (APN)	[19]
NL63	α -CoV	AFV53148.1	<i>Homo sapiens</i>	Angiotensin converting enzyme 2 (ACE2)	[20]
SARS CoV-2	β -CoV (sarbecovirus)	MN908947.3	<i>Homo sapiens</i>	ACE2	[21]
SARS-CoV-1	β -CoV (sarbecovirus)	AAP13441.1	Several species	ACE2	[22]
HKU3-8	β -CoV (sarbecovirus)	ADE34766.1	<i>Rhinolophus</i> species		[23]

BM48-31	β -CoV (sarbecovirus)	YP_003858584.1	<i>Rhinolophus blasii</i>		[23]
SX2013	β -CoV (sarbecovirus)	AIA62300.1	<i>Rhinolophus ferrumequinum</i>		[23]
MERS CoV	β -CoV (merbecovirus)	AXP07355.1	Camelus dromedariu	Dipeptidyl peptidase 4 (DPP4)	[24]
HKU4	β -CoV (merbecovirus)	YP_001039953.1	<i>Tylonycteris</i> species	DDP4	[25, 26]
HKU5	β -CoV (merbecovirus)	YP_001039962.1	<i>Pipistrellus</i> species		[25, 27]
NeoCoV	β -CoV (merbecovirus)	AGY29650.2	Neoromicia capensis	ACE2	[28, 29]
HKU9	β -CoV (nobecovirus)	YP_001039971.1	<i>Rousettus leschenaulti</i>		[27]
GCCDC 1	β -CoV (nobecovirus)	QKF94914.1	<i>Rousettus leschenaulti</i>		[30]
Zhejiang2013 (Bat Hp-beta coronavirus/Zhejiang2013)	β -CoV (hibecovirus)	YP_009072440.1	<i>Hipposideros pratti</i>		[31]
BCoV	β -CoV (embecovirus)	AAA66399.1	<i>Bovine</i> species	N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2).	[32]
OC43	β -CoV (embecovirus)	KF963240.1	<i>Homo sapiens sapiens</i>	N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2).	[33]
HKU1	β -CoV (embecovirus)	AGW27881.1	<i>Homo sapiens sapiens</i>	N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2).	[33]
HKU15	δ -CoV	YP_009513021.1	<i>Sus scrofa</i>	porcine aminopeptidase N (pAPN)	[34]

HKU22	γ-CoV	AHB63508.1	<i>Tursiops</i> species		[35]
-------	-------	------------	----------------------------	--	------

322

323

Supplementary Table 2: Characteristics of individuals shown in Figure 1.

Participant ID	Age Bracket	Sex	Time points included in this study	SARS CoV-2 infection prior to vaccination	Vaccine type
Pluto-001	45-49	Male	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-002	20-24	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Moderna
Pluto-003	55-59	Female	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-004	50-54	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-005	40-44	Female	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-006	35-39	Female	Pre vaccine, Post-vax, Post-Boost	No	Pfizer
Pluto-007	65-69	Male	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-008	50-54	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-009	25-29	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-0010	25-29	Female	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-0011	60-64	Male	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-0012	25-29	Male	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-0013	25-29	Male	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-0014	35-39	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Moderna
Pluto-0015	20-24	Female	Pre vaccine, Post-vax, Post-Boost	No	Pfizer

Pluto-0016	25-29	Female	Pre vaccine, Post-vax, Post-Boost	Yes	Pfizer
Pluto-0017	40-44	Female	Pre vaccine, Post-vax, Post-Boost	No	Moderna
Pluto-0018	40-44	Female	Pre vaccine, Post-vax, Post-Boost	No	Pfizer
Pluto-0019	30-34	Female	Pre vaccine, Post-vax, Post-Boost	No	Pfizer
Pluto-0020	35-39	Male	Pre vaccine, Post-vax, Post-Boost	Yes	Moderna

324

325 **Supplementary Table 3: Characteristics of individuals shown in Figure 2 and S Figure 1.**

326

Participant ID	Age Bracket	Sex	Time points included in this study	SARS CoV-2 infection prior to vaccination	Vaccine Type
OMI-001	30-39	Female	Post-Vax, Post-Boost	No	Moderna
OMI-002	18-29	Female	Post-Vax, Post-Boost	No	Moderna
OMI-003	40-49	Male	Post-Vax, Post-Boost	No	Moderna
OMI-004	40-49	Female	Post-Vax, Post-Boost	No	Moderna
OMI-005	40-49	Female	Post-Vax, Post-Boost	No	Moderna
OMI-006	40-49	Male	Post-Vax, Post-Boost	No	Moderna
OMI-007	50-59	Female	Post-Vax, Post-Boost	No	Moderna
OMI-008	60-69	Female	Post-Vax, Post-Boost	No	Moderna
OMI-009	30-39	Female	Post-Vax, Post-Boost	No	Moderna
OMI-010	18-29	Female	Post-Vax, Post-Boost	No	Moderna
OMI-011	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-012	18-29	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-013	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-014	50-59	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-015	18-29	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-016	70-79	Male	Post-Vax, Post-Boost	No	Pfizer
OMI-017	30-39	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-018	30-39	Female	Post-Vax, Post-Boost	No	Pfizer

OMI-019	40-29	Male	Post-Vax, Post-Boost	No	Pfizer
OMI-020	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-021	40-49	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-022	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-023	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-024	30-39	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-028	18-29	Female	Post-Infection, Post-Vax	Yes	Moderna
OMI-029	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-032	50-59	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-027	40-49	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-033	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-034	40-49	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-035	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-025	50-59	Male	Post-Infection	Yes	No vax
OMI-026	30-39	Male	Post-Infection	Yes	No vax
OMI-030	40-49	Female	Post-Infection	Yes	No vax
OMI-031	30-39	Female	Post-Infection	Yes	No vax
OMI-036	50-59	Male	Post-Vax	Yes	Moderna
OMI-037	30-39	Male	Post-Vax	Yes	Moderna
OMI-038	18-29	Male	Post-Vax	Yes	Moderna
OMI-039	30-39	Female	Post-Vax	Yes	Moderna
OMI-040	60-69	Female	Post-Vax	Yes	Moderna
OMI-041	40-49	Female	Post-Vax	Yes	Moderna
OMI-042	40-49	Female	Post-Vax	Yes	Moderna
OMI-043	60-69	Male	Post-Vax	Yes	Moderna
OMI-044	40-49	Male	Post-Vax	Yes	Moderna
OMI-045	30-39	Male	Post-Boost	Yes	Pfizer
OMI-046	30-39	Female	Post-Boost	Yes	Pfizer
OMI-047	50-59	Female	Post-Boost	Yes	Pfizer
OMI-048	60-69	Male	Post-Boost	Yes	Pfizer
OMI-049	60-69	Male	Post-Boost	Yes	Pfizer
OMI-050	30-39	Female	Post-Boost	Yes	Pfizer

OMI-051	50-59	Female	Post-Boost	Yes	Pfizer
OMI-052	50-59	Female	Post-Boost	Yes	Pfizer
OMI-053	18-29	Female	Post-Boost	Yes	Pfizer
OMI-054	30-39	Female	Post-Boost	Yes	Pfizer

327

328

329

330 **Figure legends**

331 **Figure 1. Induction of antibodies to diverse *Orthocoronavirinae* spike proteins.** **A** shows a phylogenetic
332 tree built with amino acid sequences of the spike proteins used in this study. The tree was built using
333 Clustal Omega, visualized in FigTree and labels and highlighting was added in Microsoft Powerpoint. The
334 scale bar indicates a 5% change in amino acid sequence. Accession numbers and full name of the different
335 viruses strains used can be found in **Supplementary Table 1**. **B-D** Reactivity of longitudinal serum samples
336 from naïve (black) or SARS-CoV-2 pre-infected (grey) individuals at a pre-vaccination time point, after the
337 1st dose of COVID-19 mRNA vaccine and after the 2nd dose of COVID-19 mRNA against the ancestral spike
338 of SARS-CoV-2, against the Beta variant spike and against the Omicron BA.1 variant spike. **C-R** shows
339 reactivity to diverse β -CoV spikes, **S-T** shows reactivity to α -CoV spikes, **U** shows reactivity to a δ -CoV
340 spike and **V** shows reactivity to a γ -CoV spike. N=10 per group. Subject characteristics can be found in
341 **Supplemental Table 2**.

342
343 **Figure 2. Cross-sectional reactivity of human sera from different exposure groups to diverse**
344 ***Orthocoronavirinae* spike proteins.** **A** shows serum reactivity of pre-pandemic serum sample to different
345 spike proteins (n=15). **B** shows serum reactivity of SARS-CoV-2 convalescent individuals to different spike
346 proteins (n=16). **C** shows serum reactivity of individuals vaccinated 2x with COVID-19 mRNA vaccines, **D**
347 shows serum reactivity of individuals who got three doses of vaccine (n=20 for each group) to different
348 spike proteins. **E** and **F** show serum reactivity of individuals infected with SARS-CoV-2 and then vaccinated
349 twice (n=20 except for SX2013 where n=19) or three times (n=9) to different spike proteins. Subject
350 characteristics can be found in **Supplemental Table 3**.

351
352 **Extended Figure 1: Percent of individuals with reactivity above the limit of detection (LoD) to different**
353 **spike proteins for each group shown in Figure 1.** **A** shows percentage of pre-pandemic serum samples
354 reactive to different spike proteins (n=15). **B** shows percentage of samples from SARS-CoV-2 convalescent
355 individuals reactive to different spike proteins (n=16). **C** shows percentage of individuals vaccinated 2x
356 with COVID-19 mRNA vaccines reactive to different spikes, **D** shows the same for individuals who got three
357 doses of vaccine (n=20 for each group). **E** and **F** show percentage of individuals infected with SARS-CoV-2
358 and then vaccinated twice (n=20 except for SX2013 where n=19) or three times (n=9) who had reactivity
359 to different spike proteins. Subject characteristics can be found in **Supplemental Table 3**.

360

361





